<?xml version="1.0" encoding="UTF-8"?>
<GaPExchange xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:noNamespaceSchemaLocation="./dbGaPEx2.1.5.xsd">

<MetaVariables>
	<Submitter/>
	<Method/>
</MetaVariables>
<MetaLinks/>

<Projects>
	<Project/>
</Projects>

<Studies>

<Study source="dbGaP" accession="phs000617.v1.p1" parentStudy="phs000617.v1.p1" createDate="2013-04-30" modDate="2013-04-30">

<Configuration>
	<Data_Provider><![CDATA[
		<table border="1">
		<tr><th>Title</th><th>Name</th><th>Institute</th></tr>
		<tr><td>Principal Investigator</td><td>Dan Roden, MD</td><td>Vanderbilt University Medical Center, Nashville, TN, USA</td></tr>
		<tr><td>Institute</td><td>Vanderbilt University PGRN Group (PAT)</td><td>Vanderbilt University Medical Center, Nashville, TN, USA</td></tr>
		<tr><td>Funding Source</td><td>Fondation Leducq 05 CVD 01 Preventing Sudden Cardiac Death</td><td>Fondation Leducq, Paris, France</td></tr>
		<tr><td>Funding Source</td><td>HL065962</td><td>National Institutes of Health, Bethesda, MD, USA</td></tr>
		</table>
	]]></Data_Provider>
	<StudyNameEntrez>KCNE1Polymorphism as Possible Modulator of Drug-Induced TdP</StudyNameEntrez>
	<StudyNameReportPage>PGRN-Leducq: Identification of the KCNE1 D85N Polymorphism as a Possible Modulator of Drug-Induced Torsades de Pointes</StudyNameReportPage>
	<StudyTypes>
		<StudyType>Case-Control</StudyType>
	</StudyTypes>
	<Description><![CDATA[
<p>The goal of this study was to search for genetic variants that could be responsible for modifying the risk of drug-induced long QT syndrome (diLQTS). diLQTS is a relatively common adverse drug event and has been a leading cause for drug relabeling and withdrawal from the market. Our hypothesis, that variants in genes which regulate electrical properties in the heart modify the risk of diLQTS, was tested by genotyping patients of European descent at 1424 single nucleotide polymorphisms (SNPs) in 18 candidate genes. We found that the SNP KCNE1 D85N was highly predictive of diLQTS with an odds ratio of 9.0 (95% confidence interval: 3.5-22.9).</p>]]>
	</Description>
	<StudyInEx><![CDATA[
<p>Inclusion criteria for Cases:<br/> Cases were defined as those subjects &#8805;18 years of age at the time of an incident of drug-induced LQTS and/or TdP who had one of the following: <ol> <li>An uncorrected QT interval &#8805;600 msec while on drug that decreased to &#60;480 msec following withdrawal of drug;</li> <li>A change in uncorrected QT interval of at least 100 msec (either from the pre-exposure to the during-exposure ECG or from the during-exposure to the post-exposure ECG) with an uncorrected QT interval &#62;480 msec while on drug; or</li> <li>An episode of ECG-documented TdP with a subsequent ECG with no evidence of TdP following withdrawal of drug.</li> </ol> </p> <p>Exclusion criteria for Cases:<br/> <ol> <li>Potassium level &#8804;3 mmol at onset of event (1 mEq = 1 mmol);</li> <li>Subarachnoid hemorrhage at onset of event;</li> <li>Cardiac bypass &#60;24 hours before onset of event;</li> <li>Hospital admission diagnosis of hypothermia at time of event;</li> <li>Diagnosed with congenital LQTS prior to onset of event;</li> <li>Currently leukopenic (WBC&#60;1000 cells/mL);</li> <li>Has had a non-autologous bone marrow transplant at anytime in the past.</li> </ol> </p> <p>Inclusion criteria for Controls:<br/> <ol> <li>18 years of age or older;</li> <li>New start on QT-prolonging antiarrhythmic drug(s);</li> <li>Has not received a blood transfusion in the past 4 months.</li> </ol> </p>]]>
	</StudyInEx>
	<StudyProjects>
		<Project/>
	</StudyProjects>
	<Publications>
		<Publication>
			<Pubmed pmid="22100668"/>
		</Publication>
	</Publications>
	<Diseases>
		<Disease vocab_source="MESH" vocab_term="Long QT Syndrome"/>
		<Disease vocab_source="MESH" vocab_term="Torsades de Pointes"/>
	</Diseases>
	<Attributions>
		<Header title="Principal Investigator">
			<AttName>Dan Roden, MD</AttName>
			<Institution>Vanderbilt University Medical Center, Nashville, TN, USA</Institution>
		</Header>
		<Header title="Institute">
			<AttName>Vanderbilt University PGRN Group (PAT)</AttName>
			<Institution>Vanderbilt University Medical Center, Nashville, TN, USA</Institution>
		</Header>
		<Header title="Funding Source">
			<AttName>Fondation Leducq 05 CVD 01 Preventing Sudden Cardiac Death</AttName>
			<Institution>Fondation Leducq, Paris, France</Institution>
		</Header>
		<Header title="Funding Source">
			<AttName>HL065962</AttName>
			<Institution>National Institutes of Health, Bethesda, MD, USA</Institution>
		</Header>
	</Attributions>
	<DisplayPublicSummary>yes</DisplayPublicSummary>
	<ConsentGroups>
		<ConsentGroup groupNum="1" shortName="HMB" longName="Health/Medical/Biomedical"/>
	</ConsentGroups>
</Configuration>

  <AuthorizedAccess>
    <DacInfo ssDacId="0">
      <DacName>NHLBI</DacName>
      <DacFullName>National Heart, Lung, and Blood Institute DAC</DacFullName>
      <DacEmail>0</DacEmail>
      <DacPhone></DacPhone>
      <DacUrl></DacUrl>
    </DacInfo>
    <Policy Policy_ID="phs000617.v1.p1_policy" ref_ssDacId="0">
      <DisplayResearchStatement>yes</DisplayResearchStatement>
      <DisplayPublicSummary>yes</DisplayPublicSummary>
      <EmbargoLength>12</EmbargoLength>
      <YearsUntilRenewal>1</YearsUntilRenewal>
      <WeeksCancelRequest>8</WeeksCancelRequest>
      <PdfSupplementReqired>no</PdfSupplementReqired>
      <AcknowledgementText>
        <para>
          http://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=DUC&amp;view_pdf&amp;stacc=phs000617.v1.p1
        </para>
      </AcknowledgementText>
      <DocumentSet>
        <DataUseCertificate Label="Data Use Certificate" FilePath="https://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=DUC&amp;view_pdf&amp;stacc=phs000617.v1.p1" FileName=""/>
      </DocumentSet>
    </Policy>
    <ConsentGroups>
      <ParticipantSet groupNum-REF="1">
        <ConsentName>Health/Medical/Biomedical</ConsentName>
        <ConsentAbbrev>HMB</ConsentAbbrev>
        <UseLimitation>Use of this data is limited to health/medical/biomedical purposes, does not include the study of population origins or ancestry.
The informed consent document signed by the study participants allows use of these data by investigators employed by non-profit and for-profit organizations. These data may be used by only for genetic studies to learn about, prevent, or treat health problems.</UseLimitation>
        <IrbRequired>No</IrbRequired>
      </ParticipantSet>
    </ConsentGroups>
  </AuthorizedAccess>


</Study>

</Studies>

</GaPExchange>
